240
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Highly increased risk of fracture in patients with myeloproliferative neoplasm

, , , , &
Pages 211-217 | Received 16 Jun 2020, Accepted 22 Aug 2020, Published online: 10 Sep 2020
 

Abstract

The risk for hip and vertebral fracture was determined in 10,752 patients diagnosed with myeloproliferative neoplasms (MPN) in Sweden 1995–2015. The mean follow-up time were 6.34 years. Five percent developed hip fracture and 1.3% a vertebral fracture. There was a significant increased risk for fracture among the MPN patients compared with the Swedish population. The ratio of observed (obs) and expected (exp) number of hip fracture in all MPN patients, polycythemia vera (PV), essential thrombocythemia and MPN undetermined (MPNu) was 1.20 (95% confidence interval (CI): 1.10–1.31), 1.37 (95% CI: 1.19–1.58), 1.02 (95% CI: 0.87–1.19), and 1.28 (95% CI: 1.07–1.52), respectively. Corresponding figures for vertebral fractures were 1.94 (95% CI: 1.64–2.29), 2.09 (95% CI: 1.56–2.75), 1.50 (95% CI: 1.06–2.07) and 2.47 (95% CI: 1.77–3.35), respectively. Patients with MPN had an increased risk of hip and vertebral fracture, especially patients with PV and MPNu in comparison with the entire Swedish population.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The study was supported by grants from FOU Western Region Sweden.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.